Literature DB >> 22492917

Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization.

Suzie Thenin1, Emmanuelle Roch1, Tanawan Samleerat2,1, Thierry Moreau3, Antoine Chaillon1, Alain Moreau1, Francis Barin1, Martine Braibant1.   

Abstract

The recently described anti-human immunodeficiency virus type 1 (HIV-1) human mAb PG9 and PG16 are cross-clade broadly neutralizing. Therefore, it can be postulated that the targeted epitope(s) are highly conserved among variants of the entire group M. We analysed the sensitivity to PG9 and PG16 of pseudotyped viruses carrying envelope glycoproteins from the viral quasispecies of three HIV-1 clade CRF01_AE-infected patients. The broad heterogeneity in sensitivity to PG9 and PG16, despite closely genetically related envelope glycoproteins issued from single individuals, allowed us to identify two gp120 cross-clade conserved residues, a lysine at position 168 in the V2 loop and an isoleucine at position 215 in the C2 region, whose substitutions were associated with resistance to PG9 and PG16. By site-directed mutagenesis, we confirmed both in clades B and CRF01_AE that the substitutions K168E and I215M have a major impact on PG9 and PG16 neutralization sensitivity of pseudotyped viruses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22492917     DOI: 10.1099/vir.0.042614-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Ivelin Georgiev; Sijy O'Dell; Gwo-Yu Chuang; Ryan P Staupe; Jason S McLellan; Jason Gorman; Marie Pancera; Mattia Bonsignori; Barton F Haynes; Dennis R Burton; Wayne C Koff; Peter D Kwong; John R Mascola
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

2.  Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.

Authors:  Syna Kuriakose Gift; Daniel P Leaman; Lei Zhang; Arthur S Kim; Michael B Zwick
Journal:  J Virol       Date:  2017-11-30       Impact factor: 5.103

Review 3.  Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies.

Authors:  F Benjelloun; P Lawrence; B Verrier; C Genin; S Paul
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

4.  Conformational epitope consisting of the V3 and V4 loops as a target for potent and broad neutralization of simian immunodeficiency viruses.

Authors:  Takeo Kuwata; Kaori Takaki; Kazuhisa Yoshimura; Ikumi Enomoto; Fan Wu; Ilnour Ourmanov; Vanessa M Hirsch; Masaru Yokoyama; Hironori Sato; Shuzo Matsushita
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

5.  Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers.

Authors:  Steven W de Taeye; Eden P Go; Kwinten Sliepen; Alba Torrents de la Peña; Kimberly Badal; Max Medina-Ramírez; Wen-Hsin Lee; Heather Desaire; Ian A Wilson; John P Moore; Andrew B Ward; Rogier W Sanders
Journal:  J Biol Chem       Date:  2019-02-06       Impact factor: 5.157

Review 6.  Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies.

Authors:  Zehua Sun; Lixin Yan; Jiansong Tang; Qian Qian; Jerica Lenberg; Dandan Zhu; Wan Liu; Kao Wu; Yilin Wang; Shiqiang Lu
Journal:  Virus Res       Date:  2017-10-16       Impact factor: 3.303

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.